Login to Your Account

The ‘eyes’ do not have it: Shire gets CRL on dry eye drug

By Cormac Sheridan
Staff Writer

Monday, October 19, 2015
DUBLIN – Shire plc is betting that the outcome of a phase III trial of its dry eye treatment lifitegrast will be enough to get the drug over the line, following a complete response letter (CRL) issued by the FDA.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription